Stockscreener 앱 받기
20.52
12.68%
-2.98
전일 마감가:
$23.50
열려 있는:
$21.54
하루 거래량:
7.19M
Relative Volume:
2.91
시가총액:
$1.98B
수익:
$610.16M
순이익/손실:
$-532.93M
주가수익비율:
-3.7115
EPS:
-5.5287
순현금흐름:
$-442.30M
1주 성능:
-16.92%
1개월 성능:
-14.89%
6개월 성능:
-29.17%
1년 성능:
-52.85%
1일 변동 폭
$19.61
$23.17
1주일 범위
$19.61
$24.68
52주 변동 폭
$18.41
$46.27
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
20.52 | 2.27B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) - Yahoo Finance
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - TMX Newsfile
Ultragenyx cuts 10% of workforce as it targets 2027 profitability - The Pharma Letter
Ultragenyx Plans Workforce Reduction Following FDA Rejection of Gene Therapy Treatment - geneonline.com
Ultragenyx Shareholders Must Apply for Class Action Lawsuit Participation by April 6, 2026 - geneonline.com
Movement Recap: Is Ultragenyx Pharmaceutical Inc stock good for income investorsGlobal Markets & Stepwise Trade Signal Implementation - baoquankhu1.vn
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - marketscreener.com
Understanding the Setup: (RARE) and Scalable Risk - Stock Traders Daily
Ultragenyx Gene Therapy Progress And Restructuring Meet Deeply Discounted Valuation - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 (2026-02-15) - Seeking Alpha
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
What’s the outlook for Ultragenyx Pharmaceutical Inc.’s sector2025 Winners & Losers & Low Risk High Reward Ideas - mfd.ru
How Ultragenyx Pharmaceutical Inc. stock reacts to Fed rate cuts2025 Stock Rankings & Smart Allocation Stock Tips - mfd.ru
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript - Insider Monkey
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A - Insider Monkey
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to - pharmiweb.com
Biopharma bites: Layoffs at Ultragenyx, Gilead's licensing deal, plus a pair of PIPEs and a 340B update - FirstWord Pharma
Ultragenyx Pharmaceutical Class Action Update - Intellectia AI
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ChartMill
Ultragenyx (RARE) Faces Revenue Shortfall and Workforce Reductio - GuruFocus
Ultragenyx Earnings Call Balances Growth With Risk - TipRanks
Ultragenyx Q4 loss wider than expected, revenues increase Y/Y - MSN
Ultragenyx falls as guidance trails consensus amid job cuts - Seeking Alpha
Ultragenyx cuts jobs as it seeks path to profit in 2027 - BioPharma Dive
Why Is Ultragenyx Stock Sinking Friday?Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Asianet Newsable
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - Finviz
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down on Disappointing Earnings - MarketBeat
Ultragenyx to cut 130 jobs following failed rare-disease drug trialSan Francisco Business Times - The Business Journals
Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Truist Cuts Price Target on Ultragenyx Pharmaceutical to $76 From $90, Keeps Buy Rating - marketscreener.com
Ultragenyx Pharmaceutical Q4 2025 Earnings Call Transcript - MarketBeat
Ultragenyx (RARE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans - Fierce Biotech
Ultragenyx Pharmaceutical Class Action Lawsuit Announced - Intellectia AI
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx - GlobeNewswire
ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Ultragenyx Q4 2025 sees revenue growth, stock dips - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q4 EPS -$1.29, vs. FactSet Est of -$1.09 - marketscreener.com
Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):